Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 2/20 | 1.00 |
| ▸ | CYP2E1 | P05181 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801691 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL29929086 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL4883453 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL4885722 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL17301612 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL29928887 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL17301613 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL20668179 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL20668234 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL29929493 | 1.00 | LTA4H (1.00) | LTA4HCYP3A4CYP2C8CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-04-23 | — | — | US | disclosed |
| US-20220289657-A1 | COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289657-A1 | COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | HSD11B1, GRHPR, TIPRL | LTA4H 171/4885CYP3A4 892/4885CYP2C8 2626/4885 |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | LSS, F2R, CFTR | LTA4H 85/4885CYP3A4 508/4885CYP2C8 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.